BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

15 articles for H Fischer

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery of highly selective brain-penetrant vasopressin 1a antagonists for the potential treatment of autism via a chemogenomic and scaffold hopping approach.EBI
F. Hoffmann-La Roche
3-Amido-3-aryl-piperidines: A Novel Class of Potent, Selective, and Orally Active GlyT1 Inhibitors.EBI
F. Hoffmann-La Roche
ß-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease.EBI
F. Hoffmann-La Roche
Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells.EBI
Centre Hospitalier Universitaire Vaudois (Chuv) and University of Lausanne (Unil
Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia.EBI
F. Hoffmann-La Roche
Discovery of the imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepine scaffold as a novel, potent and selective GABA(A) alpha5 inverse agonist series.EBI
F. Hoffmann-La Roche
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.EBI
F. Hoffmann-La Roche
Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors.EBI
F. Hoffmann-La Roche
The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA alpha5 inverse agonists for the treatment of cognitive dysfunction.EBI
F. Hoffmann-La Roche
Imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepines as potent and highly selective GABAA alpha5 inverse agonists with potential for the treatment of cognitive dysfunction.EBI
F. Hoffmann-La Roche
Aryl- and heteroaryl-substituted aminobenzo[a]quinolizines as dipeptidyl peptidase IV inhibitors.EBI
F. Hoffmann-La Roche
Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.EBI
F. Hoffmann-La Roche
Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.EBI
F. Hoffmann-La Roche
Discovery of benzoylpiperazines as a novel class of potent and selective GlyT1 inhibitors.EBI
F. Hoffmann-La Roche
An aminomethylpyrimidine DPP-IV inhibitor with improved properties.EBI
F. Hoffmann-La Roche